Workflow
翔宇医疗(688626) - 2021 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2021 was ¥134,168,477.12, representing a year-over-year increase of 5.50%[5] - The net profit attributable to shareholders for the same period was ¥45,088,435.22, reflecting a growth of 16.41% compared to the previous year[5] - Total operating revenue for the first three quarters of 2021 reached ¥350,974,556.35, an increase from ¥313,084,365.25 in the same period of 2020, representing a growth of approximately 12.2%[36] - Net profit for the third quarter of 2021 was ¥130,505,114.47, compared to ¥115,864,219.86 in the previous year, reflecting an increase of about 12.5%[36] - The company's total operating costs for the first three quarters of 2021 were ¥245,845,636.92, compared to ¥214,251,728.52 in 2020, which is an increase of about 14.8%[36] Assets and Equity - Total assets reached ¥2,032,596,923.81, marking a significant increase of 107.08% compared to the end of the previous year[7] - The equity attributable to shareholders increased by 150.89% to ¥1,865,409,361.50, primarily due to the funds raised from the initial public offering[11] - The total current assets increased to RMB 1,655,430,527.16, compared to RMB 671,387,643.64 in 2020, reflecting a growth of about 146.5%[28] - The total liabilities decreased from ¥238,247,030.59 in the previous year to ¥168,148,508.66, a reduction of approximately 29.3%[31] - The total equity attributable to shareholders increased significantly from ¥743,518,367.16 to ¥1,865,409,361.50, marking an increase of about 150.8%[33] Research and Development - The R&D investment totaled ¥16,404,447.00 in Q3 2021, which is 12.23% of the operating revenue, an increase of 0.11 percentage points year-over-year[7] - The company plans to continue increasing its R&D investment to enhance product development and market competitiveness[11] - Research and development expenses for the third quarter of 2021 were ¥45,656,969.46, up from ¥35,106,389.52 in the same quarter of 2020, indicating a growth of approximately 30%[36] - The company obtained 15 new medical device registration certificates during the reporting period, bringing the total to 176[21] - A total of 30 new patents were granted, increasing the cumulative total to 992 patents[21] Cash Flow and Investments - The net cash flow from operating activities for the year-to-date period was ¥71,487,504.46, showing a decline of 19.29% year-over-year[5] - Cash inflow from operating activities for the first three quarters of 2021 was CNY 448,259,097.88, an increase of 17.5% compared to CNY 381,600,091.99 in the same period of 2020[43] - The net cash flow from operating activities decreased to CNY 71,487,504.46 in 2021 from CNY 88,572,231.51 in 2020, reflecting a decline of 19.3%[43] - Total cash outflow from investment activities surged to CNY 735,436,854.54 in 2021, compared to CNY 26,192,995.01 in 2020, indicating a significant increase in investment expenditures[44] - The net cash flow from investment activities was -CNY 733,490,602.94 in 2021, worsening from -CNY 21,096,020.91 in 2020[44] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 7,969[12] - Basic earnings per share for the third quarter of 2021 were ¥0.87, compared to ¥0.97 in the same quarter of the previous year[39] - The company's cash and cash equivalents amounted to RMB 768,332,442.15, up from RMB 487,241,515.01 in the previous year, indicating a growth of approximately 57.7%[24] - The ending balance of cash and cash equivalents rose to CNY 768,332,442.15 in 2021, up from CNY 478,379,815.04 in 2020, reflecting a growth of 60.7%[44] - Cash received from other operating activities increased to CNY 75,565,353.49 in 2021, compared to CNY 46,238,785.24 in 2020, representing a growth of 63.5%[43]